Effects of canagliflozin on human myocardial redox signalling: clinical implications

Eur Heart J

28 July Jul 2021 one month ago
  • Stadiotti I, Sommariva E

Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibitory effects, on myocardial redox signalling in humans.

Reference

Effects of canagliflozin on human myocardial redox signalling: clinical implications. Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C. Eur Heart J. 2021 Jul 19:ehab420. doi: 10.1093/eurheartj/ehab420

Go to PubMed